
Inside Takeda’s R&D transformation
Deals and acquisitions, filling in pipeline gaps, externalizing assets that are no longer a good fit. What really goes on when pharma companies restructure their R&D approach?
Deals and acquisitions, filling in pipeline gaps, externalizing assets that are no longer a good fit. What really goes on when pharma companies restructure their R&D approach?